FDA Grants Orphan Drug Designation to BDC-1001 in Gastric Cancers
The FDA has given an orphan drug designation to BDC-1001 for the treatment of patients with gastric cancers, including gastroesophageal junction cancer.
United States South Korea Editha Perez Bolt Therapeutics Inc Immune Stimulating Antibody Conjugate Bolt Therapeutics
Source: onclive.com